[4,5]-fused-3,6-disubstituted-pyridazines with sulfur-containing substituents in position three for the treatment of neoplasia

US6486158B1 · kind B1 · utility

Assignee

• Cell Pathways, Inc. · US

Inventors

• Xiaojing Wang · Foster City, US
• Gerhard Sperl · North Wales, US
• Paul Gross · Darmstadt, DE
• Rifat Pamukcu · Spring House, US
• Gary A. Piazza · Doylestown, US

Key dates

• Filing date: Jun 6, 2001
• Grant date: Nov 26, 2002
• Expiry date: Jun 6, 2021

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D237/32
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

[4,5]-Fused-3,6 disubstituted-pydidazines of Formula I are useful for inducing or promoting apoptosis and for arresting uncontrolled neoplastic cell proliferation, and are specifically useful in the arresting and treatment of neoplasia: whereinY1 and Y2 are independently selected from the group consisting of (CH2)n,—C(X)—NH—,—(CH2)n—C(X)—O—, and X is O or S;R1 is selected from the group consisting of lower alkyl, lower alkenyl, lower alkynyl, and substituted or unsubstituted phenyl, pyridinyl, and the like;R2 is selected from the group consisting of substituted or unsubstituted phenyl, benzyl, pyridinyl, and the like;“A” is a benzene ring fused with the pyridazine ring; andR3 is independently selected in each instance form the group consisting of halogen, lower alkyl, and the like.